

Karin Haustermans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7355165/publications.pdf>

Version: 2024-02-01

268

papers

16,261

citations

20817

60

h-index

18647

119

g-index

274

all docs

274

docs citations

274

times ranked

17009

citing authors

#	ARTICLE	IF	CITATIONS
1	Gastric cancer. Lancet, The, 2016, 388, 2654-2664.	13.7	1,560
2	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2010, 11, 835-844.	10.7	1,532
3	Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial) Tj ETQq1 1 0.784314 rgBT /Overlo	13.7	1,096
4	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, The, 2012, 380, 2018-2027.	13.7	759
5	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer, 2014, 50, 1.e1-1.e34.	2.8	349
6	Diffusion-Weighted MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal Cancer: A Multicenter Study. Annals of Surgical Oncology, 2011, 18, 2224-2231.	1.5	335
7	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163.	0.6	275
8	Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 787-796.	1.6	267
9	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. Journal of Clinical Oncology, 2010, 28, 4450-4456.	1.6	254
10	Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. European Urology, 2013, 63, 450-458.	1.9	216
11	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. Cancer Cell, 2018, 34, 1012-1026.e3.	16.8	209
12	Definition and delineation of the clinical target volume for rectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1129-1142.	0.8	203
13	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 2017, 24, 2252-2258.	1.5	186
14	Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiotherapy and Oncology, 2003, 68, 69-74.	0.6	183
15	Value of Diffusion-Weighted Magnetic Resonance Imaging for Prediction and Early Assessment of Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: Preliminary Results. International Journal of Radiation Oncology Biology Physics, 2012, 82, 863-870.	0.8	178
16	Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. European Urology, 2012, 62, 472-487.	1.9	157
17	Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 2011, 12, 255.	1.6	156
18	The role of diffusion-weighted MRI and 18F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review. Radiotherapy and Oncology, 2014, 113, 158-165.	0.6	155

#	ARTICLE	IF	CITATIONS
19	Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. Journal of Magnetic Resonance Imaging, 2013, 37, 1392-1401.	3.4	150
20	Targeting the Hedgehog signaling pathway in cancer: beyond Smoothed. Oncotarget, 2015, 6, 13899-13913.	1.8	148
21	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, Tj ETQq1 1 0 2 8 4 3 1 4 rg 3 4 / Over	2.8	144
22	Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases. European Urology, 2011, 60, 125-130.	1.9	142
23	International consensus guidelines on Clinical Target Volume delineation in rectal cancer. Radiotherapy and Oncology, 2016, 120, 195-201.	0.6	141
24	The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiotherapy and Oncology, 1999, 50, 13-23.	0.6	139
25	Microscopic Vascular Invasion is the Most Relevant Prognosticator After Radical Nephrectomy for Clinically Nonmetastatic Renal Cell Carcinoma. Journal of Urology, 1997, 158, 45-49.	0.4	137
26	T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy. Clinical Cancer Research, 2008, 14, 4883-4890.	7.0	135
27	Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiotherapy and Oncology, 2014, 110, 3-8.	0.6	132
28	EORTC-ROG expert opinion: Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiotherapy and Oncology, 2009, 92, 164-175.	0.6	130
29	Impact of Interval between Neoadjuvant Chemoradiotherapy and TME for Locally Advanced Rectal Cancer on Pathologic Response and Oncologic Outcome. Annals of Surgical Oncology, 2012, 19, 2833-2841.	1.5	130
30	The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncologica, 2010, 49, 956-963.	1.8	126
31	Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiotherapy and Oncology, 2004, 73, 269-275.	0.6	121
32	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2014, 66, 479-486.	1.9	121
33	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
34	Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 901-908.	0.8	114
35	The Value of Magnetic Resonance Imaging for Radiotherapy Planning. Seminars in Radiation Oncology, 2014, 24, 151-159.	2.2	113
36	Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiotherapy and Oncology, 2020, 147, 92-98.	0.6	109

#	ARTICLE	IF	CITATIONS
37	Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation. <i>Cancer Research</i> , 2018, 78, 659-670.	0.9	107
38	Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. <i>Radiotherapy and Oncology</i> , 2015, 115, 186-190.	0.6	102
39	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 728-733.	1.9	102
40	Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. <i>Radiotherapy and Oncology</i> , 2018, 127, 74-80.	0.6	101
41	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 709-713.	0.8	99
42	Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas. <i>Annals of Surgery</i> , 2006, 243, 334-340.	4.2	98
43	Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13979-14007.	4.1	95
44	Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2751-2757.	1.6	94
45	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
46	Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. <i>Radiotherapy and Oncology</i> , 2011, 98, 126-133.	0.6	89
47	Dose prescription and treatment planning based on FMISO-PET hypoxia. <i>Acta Oncologica</i> , 2012, 51, 222-230.	1.8	85
48	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017, 71, 886-893.	1.9	77
49	Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?. <i>Acta Oncologica</i> , 2008, 47, 1237-1248.	1.8	76
50	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. <i>European Journal of Cancer</i> , 2013, 49, 2784-2790.	2.8	76
51	Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. <i>Radiotherapy and Oncology</i> , 1998, 47, 149-153.	0.6	75
52	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016, 63, 11-24.	2.8	73
53	Radiotherapy for Bladder Cancer. <i>Urology</i> , 2007, 69, 80-92.	1.0	68
54	The Benefits of Including Clinical Factors in Rectal Normal Tissue Complication Probability Modeling After Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1233-1242.	0.8	68

#	ARTICLE	IF	CITATIONS
55	International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiotherapy and Oncology, 2020, 148, 213-215.	0.6	65
56	Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e23-109.e31.	1.6	63
57	Image guidance in radiation therapy for better cure of cancer. Molecular Oncology, 2020, 14, 1470-1491.	4.6	63
58	PET-based treatment planning in radiotherapy: a new standard?. Journal of Nuclear Medicine, 2007, 48 Suppl 1, 68S-77S.	5.0	62
59	A kernel-based integration of genome-wide data for clinical decision support. Genome Medicine, 2009, 1, 39.	8.2	61
60	Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. Radiotherapy and Oncology, 2012, 104, 192-198.	0.6	61
61	EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologist's expert review. Radiotherapy and Oncology, 2014, 110, 195-198.	0.6	61
62	Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics. Radiotherapy and Oncology, 2020, 142, 246-252.	0.6	61
63	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	1.9	60
64	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Journal of Clinical Oncology, 2021, 39, 17-29.	1.6	58
65	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 179-193.	4.4	57
66	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993.	2.8	56
67	Outcome measures in multimodal rectal cancer trials. Lancet Oncology, The, 2020, 21, e252-e264.	10.7	56
68	Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. European Journal of Radiology, 2012, 81, e217-e222.	2.6	55
69	A Pretreatment Table for the Prediction of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer. European Urology, 2007, 51, 388-396.	1.9	54
70	What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?. Cancer Treatment Reviews, 2014, 40, 60-67.	7.7	52
71	Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer. Clinical Cancer Research, 2011, 17, 3469-3477.	7.0	51
72	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. Journal of Clinical Oncology, 2014, 32, 3501-3501.	1.6	51

#	ARTICLE	IF	CITATIONS
73	Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiotherapy and Oncology, 2010, 96, 339-346.	0.6	50
74	Tumour Movement in Proton Therapy: Solutions and Remaining Questions: A Review. Cancers, 2015, 7, 1143-1153.	3.7	49
75	Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac. Radiotherapy and Oncology, 2018, 128, 479-484.	0.6	49
76	Non-invasive tumour perfusion measurement by dynamic CT: preliminary results. Radiotherapy and Oncology, 1997, 44, 159-162.	0.6	48
77	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	1.9	48
78	[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 209-218.	6.4	47
79	Biological Image-Guided Radiotherapy in Rectal Cancer: Challenges and Pitfalls. International Journal of Radiation Oncology Biology Physics, 2009, 75, 782-790.	0.8	47
80	IGRT in rectal cancer. Acta Oncologica, 2008, 47, 1317-1324.	1.8	46
81	The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. , 1999, 85, 803-811.		44
82	Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1486-1492.	0.8	44
83	Magnetic resonance imaging for prostate cancer radiotherapy. Physica Medica, 2016, 32, 446-451.	0.7	43
84	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. Radiotherapy and Oncology, 2020, 148, 194-200.	0.6	43
85	EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients. Clinical Cancer Research, 2011, 17, 5161-5169.	7.0	42
86	Intrafractional prostate motion during online image guided intensity-modulated radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 98, 181-186.	0.6	42
87	Where next with preoperative radiation therapy for rectal cancer?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 597-602.	0.8	40
88	Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. European Urology Oncology, 2021, 4, 305-309.	5.4	40
89	Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. European Journal of Cancer, 2022, 166, 254-269.	2.8	40
90	Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiation Oncology, 2007, 2, 29.	2.7	38

#	ARTICLE	IF	CITATIONS
91	Double blind randomized phase II study with radiation+5-fluorouracil±celecoxib for resectable rectal cancer. Radiotherapy and Oncology, 2009, 93, 273-278.	0.6	38
92	The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo. Oncotarget, 2016, 7, 84286-84298.	1.8	38
93	Molecular responses of rectal cancer to preoperative chemoradiation. Radiotherapy and Oncology, 2006, 80, 172-177.	0.6	37
94	A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiotherapy and Oncology, 2010, 97, 474-479.	0.6	37
95	Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer. Radiotherapy and Oncology, 2017, 124, 104-109.	0.6	37
96	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	1.9	36
97	Validation and IMRT/VMAT delivery quality of a preconfigured fast-rotating linac system. Medical Physics, 2019, 46, 328-339.	3.0	36
98	Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial. Radiotherapy and Oncology, 2018, 128, 321-326.	0.6	36
99	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Radiotherapy and Oncology, 2021, 154, 60-69.	0.6	36
100	Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: is it worthwhile to measure Tpot?. Radiotherapy and Oncology, 1998, 46, 157-167.	0.6	35
101	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget, 2016, 7, 24326-24338.	1.8	33
102	The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiotherapy and Oncology, 2006, 79, 1-14.	0.6	32
103	Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom. Radiotherapy and Oncology, 2006, 79, 190-197.	0.6	32
104	Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. European Urology, 2022, 82, 252-257.	1.9	32
105	Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1849-1861.	2.5	31
106	Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage I rectal cancer: A real standard?. Critical Reviews in Oncology/Hematology, 2017, 114, 43-52.	4.4	30
107	DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS ONE, 2015, 10, e0130651.	2.5	30
108	Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. International Journal of Colorectal Disease, 2009, 24, 129-138.	2.2	29

#	ARTICLE	IF	CITATIONS
109	Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation. <i>Clinical Cancer Research</i> , 2010, 16, 2709-2714.	7.0	29
110	Deep learning dose prediction for IMRT of esophageal cancer: The effect of data quality and quantity on model performance. <i>Physica Medica</i> , 2021, 83, 52-63.	0.7	29
111	NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2019, 141, 33-40.	0.6	28
112	Inflammation-Based Index and ⁶⁸ Ga-DOTATOC PET-CT Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰ Y-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1014-1020.	5.0	28
113	The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 399.	4.1	27
114	Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. <i>Radiotherapy and Oncology</i> , 2000, 55, 325-333.	0.6	25
115	Influence of Time Delay on the Estimated Lung Shunt Fraction on ^{99m} Tc-Labeled MAA Scintigraphy for ⁹⁰ Y Microsphere Treatment Planning. <i>Clinical Nuclear Medicine</i> , 2013, 38, 940-942.	1.3	25
116	Individualized dosimetry-based activity reduction of ⁹⁰ Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1141-57.	6.4	25
117	Hypofractionated palliative radiotherapy for bladder cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 181-186.	2.2	25
118	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. <i>Journal of Clinical Oncology</i> , 2018, 36, 3500-3500.	1.6	25
119	Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. <i>Radiotherapy and Oncology</i> , 2008, 89, 353-360.	0.6	24
120	Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncologica</i> , 2015, 54, 896-902.	1.8	24
121	Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. <i>Radiotherapy and Oncology</i> , 2019, 140, 131-142.	0.6	24
122	Histopathological Features of MRI-Invisible Regions of Prostate Cancer Lesions. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1235-1246.	3.4	24
123	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPII. <i>Radiotherapy and Oncology</i> , 2010, 97, 36-39.	0.6	23
124	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	4.4	23
125	Multicenter validation of prostate tumor localization using multiparametric MRI and prior knowledge. <i>Medical Physics</i> , 2017, 44, 949-961.	3.0	23
126	Optimal ⁶⁸ Ga-PSMA and ¹⁸ F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1211-1218.	6.4	23

#	ARTICLE	IF	CITATIONS
127	Current practice in proton therapy delivery in adult cancer patients across Europe. <i>Radiotherapy and Oncology</i> , 2022, 167, 7-13.	0.6	23
128	Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: Prognostic value and effects of preoperative radio (chemo) therapy. <i>European Journal of Cancer</i> , 2008, 44, 791-797.	2.8	22
129	Fast, accurate, and robust automatic marker detection for motion correction based on oblique kV or MV projection image pairs. <i>Medical Physics</i> , 2010, 37, 1554-1564.	3.0	22
130	Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival. <i>Acta Oncologica</i> , 2016, 55, 486-495.	1.8	22
131	IMRT-based optimization approaches for volumetric modulated single arc radiotherapy planning. <i>Radiotherapy and Oncology</i> , 2010, 95, 149-152.	0.6	21
132	Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation. <i>Annals of Surgical Oncology</i> , 2011, 18, 684-690.	1.5	21
133	In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. <i>BMC Cancer</i> , 2015, 15, 946.	2.6	21
134	Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 437-442.	0.6	21
135	Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. <i>World Journal of Surgical Oncology</i> , 2019, 17, 89.	1.9	21
136	Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate?. <i>Radiotherapy and Oncology</i> , 1997, 45, 39-47.	0.6	20
137	The ESTRO Breur Lecture 2010: Toward a tailored patient approach in rectal cancer. <i>Radiotherapy and Oncology</i> , 2011, 100, 15-21.	0.6	20
138	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 110, 45-54.	0.6	20
139	Does a central review platform improve the quality of radiotherapy for rectal cancer? Results of a national quality assurance project. <i>Radiotherapy and Oncology</i> , 2014, 111, 400-405.	0.6	20
140	The TRENDY multi-center randomized trial on hepatocellular carcinoma – Trial QA including automated treatment planning and benchmark-case results. <i>Radiotherapy and Oncology</i> , 2017, 125, 507-513.	0.6	20
141	Prospective data registration and clinical trials for particle therapy in Europe. <i>Radiotherapy and Oncology</i> , 2018, 128, 9-13.	0.6	20
142	Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. <i>Radiotherapy and Oncology</i> , 2022, 167, 127-132.	0.6	20
143	Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. <i>Radiotherapy and Oncology</i> , 2002, 65, 105-108.	0.6	19
144	Perineal Colostomy with Appendicostomy as an Alternative for an Abdominal Colostomy: Symptoms, Functional Status, Quality of Life, and Perceived Health. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 817-824.	1.3	19

#	ARTICLE	IF	CITATIONS
145	CT- and MRI-based seed localization in postimplant evaluation after prostate brachytherapy. Brachytherapy, 2013, 12, 580-588.	0.5	19
146	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Frontiers in Surgery, 2016, 3, 65.	1.4	19
147	Modeling the dose dependence of the vis-absorption spectrum of EBT3 GafChromicâ„¢ films. Medical Physics, 2017, 44, 2532-2543.	3.0	19
148	Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification. Urology, 2019, 130, 113-119.	1.0	19
149	Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiotherapy and Oncology, 2021, 156, 102-112.	0.6	19
150	Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization. Radiotherapy and Oncology, 2018, 128, 161-166.	0.6	18
151	The Combination of Particle Irradiation With the Hedgehog Inhibitor GANT61 Differently Modulates the Radiosensitivity and Migration of Cancer Cells Compared to X-Ray Irradiation. Frontiers in Oncology, 2019, 9, 391.	2.8	18
152	Mucin-Secreting Adenocarcinoma of the Prostate with Neuroendocrine Differentiation and Paneth-Like Cells. American Journal of Surgical Pathology, 1994, 18, 200-207.	3.7	17
153	Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. Targeted Oncology, 2015, 10, 375-383.	3.6	17
154	Can clinical factors be used as a selection tool for an organ-preserving strategy in rectal cancer?. Acta OncolÃ³gica, 2016, 55, 1047-1052.	1.8	17
155	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. European Urology Focus, 2018, 4, 369-375.	3.1	17
156	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. International Journal of Radiation Oncology Biology Physics, 2013, 87, 960-967.	0.8	16
157	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in â„¥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.8	16
158	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. BMC Cancer, 2018, 18, 354.	2.6	16
159	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. European Journal of Cancer, 2020, 124, 67-76.	2.8	16
160	Clinical Target Volume Delineation for Rectal Cancer Radiation Therapy: Time for Updated Guidelines?. International Journal of Radiation Oncology Biology Physics, 2015, 91, 690-691.	0.8	15
161	Towards 3D printed multifunctional immobilization for proton therapy: Initial materials characterization. Medical Physics, 2016, 43, 5392-5402.	3.0	15
162	Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer. Medical Physics, 2018, 45, 2205-2217.	3.0	15

#	ARTICLE	IF	CITATIONS
163	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15
164	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14
165	Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1055-1062.	0.8	14
166	Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2008, , 166-77.	0.7	14
167	A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 90, 331-336.	0.6	13
168	Online adaptation and verification of VMAT. <i>Medical Physics</i> , 2015, 42, 3877-3891.	3.0	13
169	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	1.9	13
170	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. <i>Practical Radiation Oncology</i> , 2021, 11, 202-211.	2.1	13
171	Investigation of possible endogenous hypoxia markers in colorectal cancer. <i>International Journal of Radiation Biology</i> , 2013, 89, 9-15.	1.8	12
172	Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncol³gica</i> , 2013, 52, 1336-1344.	1.8	12
173	Dosimetric adaptive IMRT driven by fiducial points. <i>Medical Physics</i> , 2014, 41, 061716.	3.0	12
174	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.6	12
175	Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 41.	2.5	12
176	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11256.	1.0	12
177	Is there a future for cell kinetic measurements using IdUrd or BdUrd?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 505-511.	0.8	11
178	Moderate dose escalation with volumetric modulated arc therapy improves outcome in rectal cancer. <i>Acta Oncol³gica</i> , 2017, 56, 1501-1506.	1.8	11
179	Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. <i>Acta Oncol³gica</i> , 2019, 58, 1358-1365.	1.8	11
180	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 246.	2.8	11

#	ARTICLE	IF	CITATIONS
181	The use of patient reported outcome measures (PROMs) in palliative radiotherapy: A topical review. <i>Radiotherapy and Oncology</i> , 2020, 149, 94-103.	0.6	11
182	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
183	The biological basis of fractionation. <i>Rays</i> , 2004, 29, 231-6.	0.2	11
184	Adaptive RT in Rectal Cancer: Superior to 3D-CRT? A Simple Question, a Complex Answer. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 21-23.	2.0	10
185	¹⁸ F-FLT and ¹⁸ F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. <i>International Journal of Radiation Biology</i> , 2009, 85, 763-771.	1.8	10
186	External Beam Radiotherapy for Prostate Cancer. <i>Journal of Endourology</i> , 2010, 24, 781-789.	2.1	10
187	Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients. <i>American Journal of Pathology</i> , 2018, 188, 795-804.	3.8	10
188	Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5T magnetic resonance imaging guided linear accelerator. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 11, 16-20.	2.9	10
189	Improved repeatability of dynamic contrast-enhanced MRI using the complex MRI signal to derive arterial input functions: a test-retest study in prostate cancer patients. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3358-3369.	3.0	10
190	Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection. <i>Journal of Urology</i> , 2020, 203, 713-718.	0.4	10
191	Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1. <i>Radiotherapy and Oncology</i> , 2006, 80, 143-150.	0.6	9
192	Significant impact of transient deterioration of renal function on dosimetry in PRRT. <i>Annals of Nuclear Medicine</i> , 2013, 27, 74-77.	2.2	9
193	Which Patients With Rectal Cancer Do Not Need Radiotherapy?. <i>Seminars in Radiation Oncology</i> , 2016, 26, 199-204.	2.2	9
194	Clinical Implementation of DeepVoxNet for Auto-Delineation of Organs at Risk in Head and Neck Cancer Patients in Radiotherapy. <i>Lecture Notes in Computer Science</i> , 2018, , 223-232.	1.3	9
195	Pooled Analysis of external-beam Radiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). <i>European Journal of Cancer</i> , 2019, 121, 130-143.	2.8	9
196	Altered Biodistribution of Somatostatin Analogues After First Cycle of Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, e579-e581.	1.6	8
197	Implementation of volumetric modulated arc therapy for rectal cancer: Pitfalls and challenges. <i>Acta Oncologica</i> , 2015, 54, 1677-1681.	1.8	8
198	Do refined consensus guidelines improve the uniformity of clinical target volume delineation for rectal cancer? Results of a national review project. <i>Radiotherapy and Oncology</i> , 2016, 120, 202-206.	0.6	8

#	ARTICLE	IF	CITATIONS
199	PET imaging in adaptive radiotherapy of gastrointestinal tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 385-403.	0.7	8
200	Radiation oncology in the new virtual and digital era. Radiotherapy and Oncology, 2021, 154, A1-A4.	0.6	8
201	Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiotherapy and Oncology, 2021, 162, 98-104.	0.6	8
202	Patient Positioning Based on a Radioactive Tracer Implanted in Patients With Localized Prostate Cancer: A Performance and Safety Evaluation. International Journal of Radiation Oncology Biology Physics, 2013, 85, 555-560.	0.8	7
203	How do patients between the age of 65 and 75 use a web-based decision aid for treatment choice in localized prostate cancer?. Journal of Evidence-Based Medicine, 2013, 6, 167-172.	2.4	7
204	Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer. BMC Cancer, 2017, 17, 634.	2.6	7
205	Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. BMC Cancer, 2020, 20, 457.	2.6	7
206	Targeting the Hedgehog pathway in combination with X-ray or carbon ion radiation decreases migration of MCF-7 breast cancer cells. International Journal of Oncology, 2019, 55, 1339-1348.	3.3	7
207	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.6	7
208	An experimental evaluation of three preoperative radiation regimens for resectable rectal cancer. Annals of Surgical Oncology, 2002, 9, 292-297.	1.5	6
209	A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma. Radiation Oncology, 2008, 3, 30.	2.7	6
210	FDG and Beyond. Recent Results in Cancer Research, 2016, 198, 163-173.	1.8	6
211	Could Autoimmune Disease Contribute to the Abscopal Effect in Metastatic Hepatocellular Carcinoma?. Hepatology, 2020, 72, 1152-1154.	7.3	6
212	Validation of an Improved Patient-Specific Mold Design for Registration of In-vivo MRI and Histology of the Prostate. Lecture Notes in Computer Science, 2016, , 36-43.	1.3	6
213	Een beslissingshulp voor patiënten met gelokaliseerde prostaatkanker: eerste resultaten. Tijdschrift Voor Geneeskunde, 2007, 63, 15-21.	0.0	6
214	Dosimetric impact of intrafraction prostate rotation and accuracy of gating, multi-leaf collimator tracking and couch tracking to manage rotation: An end-to-end validation using volumetric film measurements. Radiotherapy and Oncology, 2021, 156, 10-18.	0.6	5
215	Automated treatment planning of prostate stereotactic body radiotherapy with focal boosting on a fast-rotating ring linac: Plan quality comparison with arm linacs. Journal of Applied Clinical Medical Physics, 2021, 22, 59-72.	1.9	5
216	Reply to I. R. Vogelius et al. Journal of Clinical Oncology, 2021, 39, 3086-3087.	1.6	5

#	ARTICLE	IF	CITATIONS
217	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <i>Ecantermediscience</i> , 2020, 14, 1036.	1.1	5
218	Set-up verification on a belly-board device using electronic portal imaging. <i>Journal of Radiotherapy in Practice</i> , 2007, 6, 73-82.	0.5	4
219	Exploring Limits for Data Registration in the Context of PROCARE, a Quality Improvement Project on Rectal Cancer. <i>Acta Chirurgica Belgica</i> , 2012, 112, 15-23.	0.4	4
220	Potential benefits of dosimetric VMAT tracking verified with 3D film measurements. <i>Medical Physics</i> , 2016, 43, 2162-2173.	3.0	4
221	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , 2019, 124, 35-39.	2.5	4
222	ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies. <i>Radiotherapy and Oncology</i> , 2021, 164, 92-97.	0.6	4
223	Nonrigid Registration of Multitemporal CT and MR Images for Radiotherapy Treatment Planning. <i>Lecture Notes in Computer Science</i> , 2006, , 297-305.	1.3	4
224	Using ePROMs for follow-up after palliative radiotherapy: An exploratory study with patients and health care providers. <i>Patient Education and Counseling</i> , 2022, 105, 2355-2361.	2.2	4
225	In regard to Ciernik et al.: Automated Functional Image-Guided Radiation Treatment Planning for Rectal Cancer (<i>Int J Radiat Oncol Biol Phys</i> 2005;62:893â€“900). <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1611-1612.	0.8	3
226	In Regards to Bujko etÂal. (<i>Int J Radiat Oncol Biol Phys</i> 2007;68:313â€“316). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 639-640.	0.8	3
227	EORTC Radiation Oncology Group: 50 years of continuous accomplishments. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 150-159.	2.2	3
228	The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona. <i>Annals of Oncology</i> , 2014, 25, ii1-ii4.	1.2	3
229	Survival among clinical stage Iâ€“III rectal cancer patients treated with different preoperative treatments: A population-based comparison. <i>Cancer Epidemiology</i> , 2016, 43, 35-41.	1.9	3
230	A study to investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 50-53.	2.9	3
231	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 165-172.	1.2	3
232	Nodal Staging in Prostate Cancer: Still an Unresolved Issue. <i>European Urology</i> , 2012, 61, 1139-1141.	1.9	2
233	¹⁸ F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study. <i>EJNMMI Research</i> , 2013, 3, 59.	2.5	2
234	Hepatic radiation injury mimicking metastasis in distal esophageal cancer. <i>Acta Chirurgica Belgica</i> , 2017, 117, 250-255.	0.4	2

#	ARTICLE	IF	CITATIONS
235	The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment. Clinical and Translational Radiation Oncology, 2021, 26, 8-14.	1.7	2
236	Feasibility of CT-Only 3D Dose Prediction for VMAT Prostate Plans Using Deep Learning. Lecture Notes in Computer Science, 2019, , 10-17.	1.3	2
237	Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial. Future Oncology, 2020, 16, 2035-2044.	2.4	2
238	A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group. Clinical and Translational Radiation Oncology, 2022, 34, 1-6.	1.7	2
239	Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres. Radiotherapy and Oncology, 2022, 172, 32-41.	0.6	2
240	Upregulated expression of VEGF and Ca IX correlate with the vascular metastasis pattern of intestinal type carcinoma. Gastroenterology, 2003, 124, A184.	1.3	1
241	Surgery alone for advanced prostate cancer?. European Journal of Cancer, Supplement, 2007, 5, 157-169.	2.2	1
242	A practice survey of the evolution of rectal cancer management. Bulletin Du Cancer, 2009, 96, E45-E51.	1.6	1
243	Clinical Response of Renal Cell Carcinoma to Dexamethasone. Cancer Investigation, 2009, 27, 529-532.	1.3	1
244	How Might Knowledge of the Molecular Biology of Rectal Cancer Aid Us in Deciding Treatment?. Current Colorectal Cancer Reports, 2010, 6, 221-227.	0.5	1
245	MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES. Journal of Urology, 2015, 193, .	0.4	1
246	PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	1
247	Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study. Acta Oncologica, 2020, 59, 904-910.	1.8	1
248	A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy. Clinical Journal of Gastroenterology, 2021, 14, 1121-1125.	0.8	1
249	The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e151-e154.	3.8	1
250	The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e151-e154.	3.8	1
251	Validation of nonrigid registration for multi-tracer PET-CT treatment planning in rectal cancer radiotherapy. , 2009, , .		0
252	What Is the Role of IMRT and IGRT in Rectal Cancer?. , 2012, , 129-148.		0

#	ARTICLE	IF	CITATIONS
253	MP42-20 MAPPING OF PELVIC LYMPH NODES AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION INCLUDING PRE-SACRAL AND COMMON ILIAC REGIONS. Journal of Urology, 2014, 191, .	0.4	0
254	MP14-07 PATTERNS AND PREDICTORS OF CLINICAL RECURRENCE FOLLOWING EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY: A LONG TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0
255	MP14-08 LONG-TERM IMPACT OF ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY ON CLINICAL RECURRENCE IN PT3N0 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0
256	MP69-06 THE ROLE OF EXTENDED OR SUPER-EXTENDED LYMPH NODE DISSECTION FOR STAGING OF HIGH-RISK PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
257	MP14-11 WHEN IS THE OPTIMAL TIMING FOR SALVAGE RADIATION THERAPY IN PATIENTS WITH INCREASING PSA AFTER RADICAL PROSTATECTOMY? A PATIENT RISK STRATIFICATION MODEL BASED ON PROSTATE CANCER AGGRESSIVENESS. Journal of Urology, 2016, 195, .	0.4	0
258	PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST-PROSTATECTOMY RADIATION THERAPY: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	0
259	PD51-02 IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	0
260	Reply to Laprie A. et al. Radiotherapy and Oncology, 2019, 130, 194.	0.6	0
261	Response to Schuler et al. patient-reported outcome measures (PROMs) in palliative radiotherapy. Radiotherapy and Oncology, 2021, 154, e12.	0.6	0
262	Adjuvant therapy for pancreatic cancer: current status and future directions. Oncologia, 2004, 27, .	0.0	0
263	PRINCIPLES OF RADIOTHERAPY. , 2008, , 502-508.		0
264	Upper gastrointestinal cancers: Are all carcinomas truly carcinomas?. Journal of Clinical Oncology, 2014, 32, 20-20.	1.6	0
265	Methylation-guided stratification of patients with high-risk prostate cancer for the prediction of clinical failure.. Journal of Clinical Oncology, 2014, 32, 155-155.	1.6	0
266	Oesophageal cancer. , 2016, , 365-387.		0
267	Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012 , European Urology, 2022, .	1.9	0
268	Who needs a mean dose if you can FLAME? Radiotherapy and Oncology, 2022, , .	0.6	0